DBVT - DBV Technologies S.A.
| Previous Close | 8.35 |
| Open | 8.45 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 900 |
| Day's Range | 8.24 - 8.45 |
| 52 Week Range | 3.60 - 25.77 |
| Volume | 177,409 |
| Avg. Volume | 239,285 |
| Market Cap | 605.722M |
| Beta (3Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.27 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.79 |
- Zacks•13 days ago
DBV Technologies S.A. (DBVT) Moves to Buy: Rationale Behind the Upgrade
DBV Technologies S.A. (DBVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- GlobeNewswire•14 days ago
Monthly information regarding the total number of voting rights and total number of shares of the Company
Monthly information regarding the total number of voting rights and total number of shares.
- GlobeNewswire•22 days ago
DBV Technologies to Attend Upcoming Investor Conferences
Montrouge, France, June 3, 2019 DBV Technologies to Attend Upcoming Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a.
- GlobeNewswire•24 days ago
DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019
Montrouge, France, June 1, 2019 DBV Technologies to Present Data from Epicutaneous Immunotherapy at EAACI 2019 Data presented highlights potential long-term benefit of.
- GlobeNewswire•last month
DBV Technologies Announces Results of its 2019 Ordinary and Extraordinary General Meeting and the Appointment of Viviane Monges to the Board of Directors
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today held its Ordinary and Extraordinary General Meeting, which was chaired by Michel de Rosen, Chairman of DBV Technologies. At the General Meeting, the Company’s shareholders approved all resolutions submitted by the Board of Directors.
- GlobeNewswire•last month
DBV Technologies Announces Departure of Deputy CEO David Schilansky
Montrouge, France, May 14, 2019 DBV Technologies Announces Departure of Deputy CEO David Schilansky DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock.
- Insider Monkey•last month
Did Hedge Funds Drop The Ball On DBV Technologies SA – ADR (DBVT) ?
While the market driven by short-term sentiment influenced by uncertainty regarding the future of the interest rate environment in the US, declining oil prices and the trade war with China, many smart money investors kept their optimism regarding the current bull run in the fourth quarter, while still hedging many of their long positions. However, […]
- GlobeNewswire•2 months ago
Ordinary and Extraordinary General Meeting of May 24, 2019 - Procedures for Obtaining Preparatory Documents for the General Meeting
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today that it will hold its Ordinary and Extraordinary General Meeting on May 24, 2019 at 8:30 a.m. CEST at the Company’s headquarters located at 177-181 Avenue Pierre Brossolette – 92120 Montrouge, France. The documents for the General Meeting will also be made available to shareholders as of the date of the issuance of the convening notice.
- GlobeNewswire•2 months ago
DBV Technologies Reports March 31, 2019 Cash Position
Montrouge, France, April 30, 2019DBV Technologies Reports March 31, 2019 Cash Position DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a.
- Zacks•2 months ago
DBV Technologies S.A. (DBVT) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in DBV Technologies S.A. (DBVT).
- GlobeNewswire•3 months ago
DBV Technologies Announces Closing of Global Offering
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the settlement and delivery of an underwritten global offering of an aggregate of 6,000,000 ordinary shares reserved to specified categories of investors in (i) an offering of 2,447,500 ordinary shares in the form of 4,895,000 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe, at an offering price of $6.75 per ADS (on the basis of an exchange rate of $1.1233 = €1.00), and (ii) a private placement of 3,552,500 ordinary shares in Europe (including France), at an offering price of €12.02 per ordinary share. The number of ordinary shares (including in the form of ADSs) sold in the global offering reflect the exercise in full of the underwriters’ option to purchase additional ordinary shares (including in the form of ADSs). The total gross proceeds from the global offering, including from the exercise of the underwriters’ option to purchase additional ordinary shares (including in the form of ADSs), were approximately $81.0 million (€72.1 million), before deducting commissions and estimated offering expenses.
- GlobeNewswire•3 months ago
DBV Technologies Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Connection With its Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares (ADS)
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the underwriters for its previously announced global offering reserved to specified categories of investors have exercised in full their option to purchase 782,608 additional ordinary shares in the form of 1,565,216 American Depositary Shares (“ADSs”), at an offering price of $6.75 per ADS, before deducting commissions and estimated offering expenses (the “Option”). Each ADS represents the right to receive one-half of one ordinary share, and the offering price of $6.75 per ADS corresponds to a price of €12.02 per ordinary share (on the basis of an exchange rate of $1.1233 = €1.00). The closing of the Option is expected to occur on April 8, 2019, subject to customary closing conditions, concurrently with the balance of the global offering.
- Motley Fool•3 months ago
Why DBV Technologies Shares Soared Today
Traders cheered after the company announced the pricing details of a stock offering.
- GlobeNewswire•3 months ago
DBV Technologies Announces Pricing of $70.4 million (€62.7 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the pricing of a global offering of an aggregate of 5,217,392 ordinary shares reserved to specified categories of investors in (i) an offering of 1,664,892 ordinary shares in the form of 3,329,784 American Depositary Shares (ADSs) in the United States, Canada and certain other countries outside Europe at a public offering price of $6.75 per ADS (on the basis of an exchange rate of $1.1233 = €1.00) and (ii) a private placement of 3,552,500 ordinary shares in Europe (including France), at a public offering price of €12.02 per ordinary share. The price at which the ordinary shares (including in the form of ADSs) will be sold in the global offering is equal to the average of the trading prices of the Company’s ordinary shares on Euronext Paris over five (5) consecutive trading days chosen from among the thirty (30) trading days prior to pricing of the global offering less a discount of 8.6%.
- GlobeNewswire•3 months ago
DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares
DBV Technologies (the “Company”) (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced its intention to issue and sell, subject to market conditions, in a global offering of new ordinary shares, which may be in the form of American Depositary Shares (ADSs), up to 5,217,392 new ordinary shares, the subscription of which is reserved to specified categories of investors. The global offering will be comprised of an offering of ADSs in the United States, Canada and certain other countries outside of Europe and a private placement of ordinary shares in Europe (including France).
- GlobeNewswire•3 months ago
DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F
Montrouge, France, April 1, 2019 DBV Technologies Announces Filing of 2018 “Document de Référence” and 2018 Annual Report on Form 20-F DBV Technologies (Euronext: DBV – ISIN:.
- PR Newswire•3 months ago
Lifshitz & Miller LLP Announces Investigation of Atlas Financial Holdings, Inc., Conduent, Inc., DBV Technologies SA, Ebix, Inc., FTS International, Inc., NV5 Global, Inc., and Venator Materials PLC
NEW YORK , March 28, 2019 /PRNewswire/ -- Atlas Financial Holdings, Inc. (AFH) Lifshitz & Miller announces investigation into possible securities laws violations in connection with "actuarial work ...
- American City Business Journals•3 months ago
Peninsula biotech lines up chance to crack the peanut allergy nut
The Brisbane company next year could have FDA and European approvals for a way to protect people with peanut allergy from accidental exposures. But competitors are numerous.
- Business Wire•3 months ago
Cohen Milstein Sellers & Toll PLLC Announces Investigation of DBV Technologies S.A.
Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether DBV Technologies S.A. (“DBV” or the “Company”) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. A class action lawsuit was filed in the U.S. District Court for the District of New Jersey by another law firm on behalf of purchasers of the common stock of DBV Technologies (DBVT) between February 14, 2018 and December 9, 2018, inclusive (the “Class Period”). Viaskin Peanut is an epicutaneous immunotherapy that delivers biologically active compounds to the immune system through the skin.
- GlobeNewswire•3 months ago
FINAL DEADLINE: (DBVT) DBV Technologies S.A. Bronstein, Gewirtz & Grossman, LLC - March 18, 2019
NEW YORK, March 18, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against DBV Technologies.
- GlobeNewswire•3 months ago
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DBVT, CVS, CTL and USX
NEW YORK, March 18, 2019 -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a.
- ACCESSWIRE•3 months ago
FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against DBV Technologies S.A. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / March 18, 2019 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against DBV Technologies S.A. (''DBV ...
